Lytix Biopharma Q1 2025 - Progress in NeoLIPA but Financial Weakness for Verrica
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2025-05-19 13:16:00
Redeye comments on Lytix Biopharma’s first quarter review of 2025. The NeoLIPA study is progressing with a planned interim readout in Q3 2025. Despite the successful share issue in November 2024, Verrica currently does not have funding for the rest of 2025, which we discuss.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/